Seelos Therapeutics Inc (SEEL)

$0.53

-0.03

(-4.61%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $0.52
    $0.55
    $0.53
    downward going graph

    2.36%

    Downside

    Day's Volatility :5.91%

    Upside

    3.64%

    downward going graph
  • $0.47
    $398.40
    $0.53
    downward going graph

    11.11%

    Downside

    52 Weeks Volatility :99.88%

    Upside

    99.87%

    downward going graph

Returns

PeriodSeelos Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-80.25%
8.7%
0.0%
6 Months
-95.05%
8.0%
0.0%
1 Year
-99.85%
14.0%
0.0%
3 Years
-99.91%
17.0%
-18.2%

Highlights

Market Capitalization
1.6M
Book Value
- $17.36
Earnings Per Share (EPS)
-34.8
Wall Street Target Price
120.0
Profit Margin
0.0%
Operating Margin TTM
-1045.77%
Return On Assets TTM
-172.56%
Return On Equity TTM
-584.2%
Revenue TTM
2.0M
Revenue Per Share TTM
2.19
Quarterly Revenue Growth YOY
-28.299999999999997%
Gross Profit TTM
-46.6M
EBITDA
-27.7M
Diluted Eps TTM
-34.8
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Seelos Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 22541.51%

Current $0.53
Target $120.00

Technicals Summary

Sell

Neutral

Buy

Seelos Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Seelos Therapeutics Inc
Seelos Therapeutics Inc
-36.42%
-95.05%
-99.85%
-99.91%
-99.89%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Seelos Therapeutics Inc
Seelos Therapeutics Inc
NA
NA
NA
0.0
-5.84
-1.73
NA
-17.36
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Seelos Therapeutics Inc
Seelos Therapeutics Inc
Buy
$1.6M
-99.89%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Seelos Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 168.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 205.5% return, outperforming this stock by 305.4%

Institutional Holdings

  • WEALTH EFFECTS LLC

    2.04%
  • AdvisorShares Investments, LLC

    2.02%
  • Gendell Jeffrey L

    1.88%
  • Balyasny Asset Management LLC

    1.66%
  • Vanguard Group Inc

    1.23%
  • Modera Wealth Management, LLC

    0.69%

Company Information

seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a

Organization
Seelos Therapeutics Inc
Employees
10
CEO
Dr. Raj Mehra J.D., Ph.D.
Industry
Pharmaceuticals: Other

FAQs